SCHEMBL6355484

SCHEMBL6355484

O=C(NCc1ccccc1NCc1ccccc1)c1cccc(Cl)c1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.56
LMNA P02545 3/20 0.51
HPGD P15428 2/20 0.51
GAA P10253 1/20 0.51
TMEM97 Q5BJF2 2/20 0.51
SIGMAR1 Q99720 2/20 0.51
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 1/20 0.50
RCE1 Q9Y256 1/20 0.50
MT-CO2 P00403 4/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA3 P07451 1/20 0.49
CA6 P23280 1/20 0.49
CA5A P35218 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA13 Q8N1Q1 1/20 0.49
CA14 Q9ULX7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355939 0.84 MT-CO2 (0.53) L3MBTL1LMNATMEM97SIGMAR1ALDH1A1
SCHEMBL6355282 0.83 L3MBTL1 (0.60) L3MBTL1LMNAHPGDGAATMEM97
SCHEMBL6355306 0.82 L3MBTL1 (0.74) L3MBTL1LMNAHPGDGAATMEM97
SCHEMBL6357294 0.81 L3MBTL1 (0.55) L3MBTL1LMNAHPGDTMEM97SIGMAR1
SCHEMBL6358813 0.79 MT-CO2 (0.65) L3MBTL1LMNAHPGDTMEM97SIGMAR1
SCHEMBL6357846 0.78 SGMS2 (0.61) L3MBTL1LMNAHPGDTMEM97SIGMAR1
SCHEMBL6356912 0.78 CHRNB2 (0.59) L3MBTL1LMNAHPGDGAATMEM97
SCHEMBL6361006 0.76 L3MBTL1 (0.58) L3MBTL1LMNAHPGDTMEM97SIGMAR1
SCHEMBL6356156 0.75 ALDH1A1 (0.75) L3MBTL1LMNAHPGDGAATMEM97
SCHEMBL6356702 0.75 MAPK8 (0.57) L3MBTL1LMNAHPGDTMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 L3MBTL1 2120/4885LMNA 1197/4885HPGD 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.